Analysts at Roth Capital initiated coverage on Spark Therapeutics, Inc. ONCE with a Buy rating.
The target price for Spark Therapeutics is set to $71.
Spark Therapeutics' shares rose 3.21% to $58.50 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in